All In Biotech

Drug Trial Radar · NCT04951076

A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)

A Phase 2b, Randomized, Double Blind, Two Arm Study to Investigate the Effects of BNC210 Tablet Formulation Compared to Placebo in Adults With Post-Traumatic Stress Disorder (PTSD)

Last checked: Nov 19, 2026Latest source record: Feb 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 212 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

212

Actual

Start

Jul 27, 2021

Primary completion

Jul 25, 2023

Study completion Aug 14, 2023

Sponsor

Lead sponsor
Bionomics LimitedIndustry
Sponsor type
Industry
First posted
Jul 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the effects of BNC210 compared to placebo on Post-Traumatic Stress Disorder (PTSD) symptom severity as measured by the Clinician Administered PTSD scale for The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (CAPS-5) Total Symptom Severity Scores.

Conditions

  • Post-Traumatic Stress Disorder

Interventions

  • BNC210Drug

    BNC210 900 mg twice daily (b.i.d.) for 12 weeks

  • PlaceboDrug

    Placebo twice daily (b.i.d.) for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline on the Clinician Administered Post-Traumatic Stress Disorder (PTSD) Scale for the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (CAPS-5) Total Symptom Severity Scores After 12 WeeksTime frame: Baseline, 4 weeks, 8 weeks,12 weeks

Locations

32 sites in 2 countries. Site status is shown where the registry gives one.

  • ATTUNE Study Clinical Trial Site

    Bellflower, California

  • ATTUNE Study Clinical Trial Site

    Beverly Hills, California

  • ATTUNE Study Clinical Trial Site

    Colton, California

  • ATTUNE Study Clinical Trial Site

    Oceanside, California

  • ATTUNE Study Clinical Trial Site

    Orange, California

  • ATTUNE Study Clinical Trial Site

    Temecula, California

  • ATTTUNE Study Clinical Trial Site

    Jacksonville, Florida

  • ATTUNE Study Clinical Trial Site

    Lauderhill, Florida

  • ATTUNE Study Clinical Trial Site

    Miami Lakes, Florida

  • ATTUNE Study Clinical Trial Site

    Orlando, Florida

  • ATTUNE Study Clinical Trial Site

    Overland Park, Kansas

  • ATTUNE Study Clinical Trial Site

    Prairie Village, Kansas

  • ATTUNE Study Clinical Trial Site

    New Bedford, Massachusetts

  • ATTUNE Study Clinical Trial Site

    Las Vegas, Nevada

  • ATTUNE Study Clinical Trial Site

    Berlin, New Jersey

  • ATTUNE Study Clinical Trial Site

    Cherry Hill, New Jersey

  • ATTUNE Study Clinical Trial Site

    Cedarhurst, New York

  • ATTUNE Study Clinical Trial Site

    Staten Island, New York

  • ATTUNE Study Clinical Trial Site

    North Canton, Ohio

  • ATTUNE Study Clinical Trial Site

    Oklahoma City, Oklahoma

  • ATTUNE Study Clinical Trial Site

    West Chester, Pennsylvania

  • ATTUNE Study Clinical Trial Site

    Memphis, Tennessee

  • ATTUNE Study Clinical Trial Site

    Austin, Texas

  • ATTUNE Study Clinical Trial Site

    Dallas, Texas

  • ATTUNE Study Clinical Trial Site

    Draper, Utah

  • ATTUNE Study Clinical Trial Site

    Barnsley, United Kingdom

  • ATTUNE Study Clinical Trial Site

    Blackpool, United Kingdom

  • ATTUNE Study Clinical Trial Site

    Cannock, United Kingdom

  • ATTUNE Study Clinical Trial Site

    Leeds, United Kingdom

  • ATTUNE Study Clinical Trial Site

    Liverpool, United Kingdom

  • ATTUNE Study Clinical Trial Site

    Manchester, United Kingdom

  • ATTUNE Study Clinical Trial Site

    Stockton-on-Tees, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.